Will support continued rapid growth of IonFlux and BioFlux systems globally

The Associated Press

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 24, 2012-- Fluxion Biosciences, a privately held drug discovery tools company, announced today that it has added 4 new senior management positions and expanded sales and technical support globally. The new positions include additions of industry veterans in sales, marketing, and technical support. This added expertise will enable Fluxion to accelerate global sales of its BioFlux system for high-throughput study of cells in physiological environments, and its IonFlux system for rapid, high performance ion channel screening.

Tom Driscoll, most recently VP of Marketing at Molecular Devices, has joined Fluxion as VP of Marketing and Business Development. Tom has held a range of management positions at Molecular Devices, Becton Dickinson, and has a history of successful product launches in the cell analysis and ion channel market segments. Ali Yehia, Ph.D., most recently Director of North American Sales at Sophion, joins as Director of Global IonFlux Sales. Ali is an electrophysiologist with an extensive background in ion channels, and is well-known in the ion channel community as an automated patch clamp expert. Andrew Baxter, Ph.D., joins as European Technical Manager IonFlux, and will be based in the United Kingdom. As an electrophysiologist, Andrew has worked extensively on high throughput ion channel drug discovery with GSK, and most recently Evotec. John Battista, most recently Fluxion's Eastern Regional Manager, has taken on the new role of BioFlux Global Sales and Service Director.

Jeff Jensen, Fluxion's CEO, stated "we are delighted to have Tom, Ali, and Andy join us in these important new roles. These are all seasoned industry veterans, and their support in joining Fluxion validates the tremendous progress we've made. These additions, coupled with our existing global sales and technical support teams, will allow us to continue our rapid expansion while maintaining the highest levels of customer support in the industry." Fluxion's BioFlux system provides a convenient solution to study "in vivo" cell dynamics in a high throughput, low cost "in vitro" format.

Application areas include cardiovascular, inflammatory, cancer, and antibiotics development. The company's IonFlux system for ion channel screening is used by leading biopharma and academic institutions for basic research, high throughput screening, and safety testing. Fluxion has delivered more than 150 systems to leading institutions such as Pfizer, Novartis, Genentech, Amgen, BMS, Sanofi-Aventis, Stanford, Harvard, NIH, and many others.

About Fluxion Biosciences Fluxion Biosciences is a translational biology company that provides single cell analysis tools for use in critical research, drug discovery,

and diagnostic applications. Fluxion's proprietary microfluidic platform automates slow, complex cell analysis workflows.

Products include the BioFlux(TM) system for studying cellular interactions, the IonFlux(TM) system for automated ion channel testing, and the IsoFlux(TM) system for circulating tumor cell analysis. Systems are used by leading pharmaceutical, biotech, and research labs globally. For more information about Fluxion Biosciences, visit www.fluxionbio.com.

CONTACT: Fluxion Biosciences Tom Driscoll, 650-241-4888 VP Marketing and Business Development tdriscoll@fluxionbio.com KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL RESEARCH SCIENCE SOURCE: Fluxion Biosciences Copyright Business Wire 2012 PUB: 02/24/2012 11:00 AM/DISC: 02/24/2012 11:00 AM http://www.businesswire.com/news/home/20120224005135/

Source URL (retrieved on *04/26/2015 - 5:25pm*):
http://www.mdtmag.com/news/2012/02/will-support-continued-rapid-growth-ionflux-and-bioflux-systems-globally